May 2, 2024 | Access, clinical trials, digital health, digital tools, oncology, patient insight-gathering, reimbursement
With rapid growth comes growing pains…

The field of oncology is rapidly growing and evolving. In 2022, global spending on cancer medicines was approximately 196 billion USD, and this number is forecasted to reach $375 billion by 2027. In fact, for the past five years, the number of treated patients with cancer has seen an average annual increase of 5% globally (1). However, with rapid growth comes growing pains.
New competitors are entering the market at a rapid pace, and competition is intensifying. There are currently more than 2,000 oncology products under development. Emerging biopharma companies are responsible for over 70% of these products (up 20 percentage points from 2017) while Big Pharma has seen a declining share of the oncology pipeline, at only around 20% of products currently under development (down 15 percentage points from 2017). This competitive intensity tends to focus on smaller patient populations with multiple treatment options.
With a larger number of treatable patients, improving survival rates, more clinical trials, and increased focus on real-world evidence, the definition of ‘standard of care’ is continuously changing. As a result, treatment algorithms are becoming more complex, leading to variable uptake and use of new treatments across regions, clinics, and prescribers.
Further, the time advantage traditionally afforded to new cancer therapies has been substantially reduced due to advances in our understanding of the underlying tumor biology and the emergence of novel treatment modalities. Occasionally, the advantage disappears well before the period of exclusivity ends (2)…
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Impetus Digital launches InSite Eventâ„¢ –Â Â the most comprehensive virtual event platform for life science companies, delivered with white glove service
Myriam Prescott, Head of Ethics, Risks and Compliance – Oncology, Novartis Canada, dissects the importance of effective patient engagement and strong compliance & monitoring programs. We also dive into the…
Dr. Farah Fourcand, Author of Pandemic Manifesto, shares her experience working on the frontlines of the COVID-19 pandemic. She also dives into the psychological impact of COVID-19, lessons learned from the…
Allison Gaw, Executive Director, Corporate and Business Development at Chinook Therapeutics, discusses women in STEM, effective leadership, cross-border collaboration during COVID-19, the future of healthcare, and much more.
We explore the importance of health literacy, patient voices, and workforce wellbeing during COVID-19 with Deborah Collyar (Patient Advocates in Research), Cathryn Gunther (Population Health Alliance) & Catina O’Leary (Health…
Brent Walker, Senior Vice President of Marketing and Analytics, Patient Bond, dives into the world of psychometrics. We explore the roles of AI and machine learning in extracting psychometric insights,…
Matt Park, Vice President & General Manager (North America) at Dacadoo, explores digital health engagement and health risk quantification in the COVID-19 era, including the roles of gamification, big data,…
Dr. Mark Poznansky, Founder/Blogger at Saved By Science explores the importance of improving health literacy among the general population, along with the scientific and technological innovations that he believes could help save…
In this customer story, we summarize one of the pilot projects conducted using our new and award-winning platform: InSite Eventâ„¢.
Bogi Eliasen, Director of Health at Copenhagen Institute for Futures Studies, discusses the future of genomics, personalized health, healthcare data, digital health, and more.
